Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 284 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin, Regular, Human Clear all
Completed Phase 1Phase 2 Interventional Results available

Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents

NCT00516386
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RhIGF-1
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 30, 2026, 1:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

NCT00229268
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Sep 30, 2026, 1:47 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity

NCT07128368
View directory record Official record
Conditions
Resistance Training
Interventions
Resistance Exercise Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Sep 30, 2026, 1:47 PM EDT
Not listed Phase 2 Interventional

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

NCT03784287
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIB, MPS III B
Interventions
AX 250
Drug
Lead sponsor
Allievex Corporation
Industry
Eligibility
0 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Oakland, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of High-Intensity Interval Training Exercise in Adolescents With Hepatosteatosis

NCT04342390
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Insulin Resistance, High Intensity Interval Training, Childhood Obesity
Interventions
High-Intensity Interval Training (HIIT)
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
13 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.

NCT01995643
View directory record Official record
Conditions
Polyphenolic Compounds and Metabolism
Interventions
Active Capsule, Placebo Capsule
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

NCT01358435
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers

NCT01365117
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

NCT01093417
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics

NCT00752180
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

NCT00705536
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

NCT00370565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Sep 30, 2026, 1:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function

NCT00949663
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 30, 2026, 1:47 PM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Sep 30, 2026, 1:47 PM EDT
Terminated Phase 2 Interventional

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

NCT00351221
View directory record Official record
Conditions
Noonan Syndrome
Interventions
rhIGF-1/rhIGFBP-3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
2 Years to 16 Years
Enrollment
24 participants
U.S. locations
2
States / cities
New Hyde Park, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2007 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

NCT00356109
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Sep 30, 2026, 1:47 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ghrelin Effect on Beta Cell Function in Health and Disease

NCT01729299
View directory record Official record
Conditions
Diabetes
Interventions
Exendin (9-39), acyl ghrelin, saline
Drug
Lead sponsor
David Dalessio
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 30, 2026, 1:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

NCT00958815
View directory record Official record
Conditions
Insulin Resistance, Atherosclerosis, Cardiovascular Disease, HIV/AIDS, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
35 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 30, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Sep 30, 2026, 1:47 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance

NCT04708535
View directory record Official record
Conditions
Insulin Resistance, Insulin Sensitivity, Obesity, Inflammation
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 30, 2026, 1:47 PM EDT